192 related articles for article (PubMed ID: 37846676)
41. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
42. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
[TBL] [Abstract][Full Text] [Related]
43. [Correlation of E2a-pbx1 expression level with clinical characteristics and early response to treatment in children with acute lymphoblastic leukemia].
Gao C; Li ZG; Zhao W; Wu MY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):569-73. PubMed ID: 18549631
[TBL] [Abstract][Full Text] [Related]
44. Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia.
Orgel E; Tucci J; Alhushki W; Malvar J; Sposto R; Fu CH; Freyer DR; Abdel-Azim H; Mittelman SD
Blood; 2014 Dec; 124(26):3932-8. PubMed ID: 25349177
[TBL] [Abstract][Full Text] [Related]
45. Time point-dependent concordance and prognostic significance of flow cytometry and real time quantitative PCR for measurable/minimal residual disease detection in acute myeloid leukemia with t(8;21)(q22;q22.1).
Shang L; Cai X; Sun W; Cheng Q; Mi Y
Cytometry B Clin Cytom; 2022 Jan; 102(1):34-43. PubMed ID: 34232569
[TBL] [Abstract][Full Text] [Related]
46. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
[TBL] [Abstract][Full Text] [Related]
47. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia.
Denys B; van der Sluijs-Gelling AJ; Homburg C; van der Schoot CE; de Haas V; Philippé J; Pieters R; van Dongen JJ; van der Velden VH
Leukemia; 2013 Mar; 27(3):635-41. PubMed ID: 22945774
[TBL] [Abstract][Full Text] [Related]
48. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
49. [Prognostic Significance of Joint Detection of miR-210 and Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia].
Mei YY; Li ZG; Zhang Y; Zhang WL; Zhang PW; Wang N; Huang DS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):66-71. PubMed ID: 28245377
[TBL] [Abstract][Full Text] [Related]
50. The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Hong Y; Zhao X; Qin Y; Zhou S; Chang Y; Wang Y; Zhang X; Xu L; Huang X
Ann Hematol; 2018 Sep; 97(9):1547-1554. PubMed ID: 29705861
[TBL] [Abstract][Full Text] [Related]
51. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
Ribera J; Granada I; Morgades M; González T; Ciudad J; Such E; Calasanz MJ; Mercadal S; Coll R; González-Campos J; Tormo M; García-Cadenas I; Gil C; Cervera M; Barba P; Costa D; Ayala R; Bermúdez A; Orfao A; Ribera JM;
Br J Haematol; 2022 Feb; 196(3):670-675. PubMed ID: 34549416
[TBL] [Abstract][Full Text] [Related]
52. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
53. Impact of pretransplant minimal residual disease on the post-transplant outcome of pediatric acute lymphoblastic leukemia.
Umeda K; Hiramatsu H; Kawaguchi K; Iwai A; Mikami M; Nodomi S; Saida S; Heike T; Ohomori K; Adachi S
Pediatr Transplant; 2016 Aug; 20(5):692-6. PubMed ID: 27256540
[TBL] [Abstract][Full Text] [Related]
54. Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study.
Salah-Eldin M; Abousamra NK; Azzam H
Med Oncol; 2014 May; 31(5):938. PubMed ID: 24692146
[TBL] [Abstract][Full Text] [Related]
55. [Minimal residual disease in acute lymphoblastic leukemia: a new concept of complete remission].
Bastida Vilá P; Palacio García C; Solsona Riera M; Ortega Aramburu JJ; Sánchez de Toledo Codina J
An Pediatr (Barc); 2005 Nov; 63(5):390-5. PubMed ID: 16266612
[TBL] [Abstract][Full Text] [Related]
56. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
Baraka A; Sherief LM; Kamal NM; Shorbagy SE
Int J Hematol; 2017 Jun; 105(6):784-791. PubMed ID: 28324281
[TBL] [Abstract][Full Text] [Related]
57. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
58. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
[TBL] [Abstract][Full Text] [Related]
59. [Real-time quantitative detection of E2A-PBX1 fusion gene in children with acute lymphoblastic leukemia and its clinical application in minimal residual disease monitoring].
Zhang R; Liao J; Li G; Sun HQ; Shi YJ; Yang JY
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jun; 15(6):440-3. PubMed ID: 23791058
[TBL] [Abstract][Full Text] [Related]
60. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome.
Nyvold C; Madsen HO; Ryder LP; Seyfarth J; Svejgaard A; Clausen N; Wesenberg F; Jonsson OG; Forestier E; Schmiegelow K;
Blood; 2002 Feb; 99(4):1253-8. PubMed ID: 11830473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
